Back to Webinars
Webinars

Utilizing NULISA, A Novel Ultrasensitive Multiplex Proteomic Panel for Comprehensive Neurological Disease Profiling including ALS/MND

The Role of Biomarkers in Treating Neurological Disorders
September 16, 2026
11:00 am – 12:00 pm Australia/Melbourne
Topic:
Neurology
REGISTER NOW

Speaker

  • Caroline Chan, PhD
    Distributor Application Scientist Manager
    Alamar Biosciences
  • Katharina Stracke, PhD
    Technical Sales Representative - Proteomics
    Geneworks

Summary

With comprehensive coverage of the hallmarks of neurological disease, the NULISAseq™ Neuro 220 Panel offers unprecedented insight into the biological mechanisms involved in Alzheimer’s Disease, Parkinson’s Disease, Traumatic Brain Injury, Amyotrophic lateral sclerosis/Motor neuron disease (MND), Multiple Sclerosis and Gliomas.

Join us for a webinar to discover how the Neuro 220 panel enables researchers to detect co-pathologies and disease heterogeneity with precision.

At the end of the webinar, find out how you can apply for the Neuro 220 pilot program for researchers in Australia and New Zealand to advance your biomarker studies.

Case study spotlight at the webinar

  • Motor neuron disease (MND), including amyotrophic lateral sclerosis (ALS), remains one of the most devastating neurodegenerative disorders, marked by clinical heterogeneity, delayed diagnosis, and limited therapeutic success. A central barrier to progress has been the lack of accessible, reliable targets that capture disease biology while enabling early diagnosis and monitoring.
  • We will showcase how new precision proteomic technologies such as NULISA have transformed our ability to study ALS/MND through accessible patient biospecimens such as blood and CSF and accelerated the discovery of blood-based biomarkers associated with disease diagnosis, progression, and biological heterogeneity.
REGISTER NOW
Linkedin

Steve Williams, MD, PhD

CSO

Dr. Willams serves as the company’s Chief Scientific Officer. He was previously Chief Medical Officer at Standard Biotools and at SomaLogic where he pioneered the discipline for discovery and validation of predictive, diagnostic and prognostic models using machine-learning applied to large-plex proteomics. 20 such tests were used for drug characterization, safety and efficacy when incorporated in clinical drug trials at Pharma/Biotech and 17 different multivariate tests were validated and translated into regulated healthcare uses. Prior to SomaLogic, Dr. Williams was at Pfizer in the UK and the USA as a clinical triallist in Translational Medicine, and subsequently as VP, Global Clinical Technology. He sat on the National Advisory Council for the National Institute of Biomedical Imaging and Bioengineering, the Executive Committee for the FNIH Biomarkers Consortium, and worked with FDA and PhRMA on developing evidentiary standards for biomarker qualification. Dr. William’s medical training was in London, at Charing Cross and Westminster Medical School, followed by a PhD in medicine/physiology at the same institution and training in Radiology at the University of Newcastle Upon Tyne. Steve is co-inventor on 26 proteomics patents and author/coauthor on multiple foundational proteomics manuscripts.

Linkedin

Justin McAnear

CFO

Mr. McAnear serves as the company’s Chief Financial Officer. He brings over 25 years of operational and financial leadership experience across various sectors and was instrumental in taking 10x Genomics public in 2019, serving as its CFO for over five years. Mr. McAnear served for over 3 years as Tesla’s VP of Worldwide Finance and Operations, supporting landmark initiatives such as the Model X and Model 3 launches and Solar City acquisition.  He also held various roles at Apple and J&J earlier in his career and served as a naval officer and aviator for over 9 years.